Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXS887 in advanced solid tumors
NCT07345637Phase 1Not yet recruiting
- Sponsor
- Fosun Pharma
- Start
- Jan 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FXS887 in solid tumor, sponsored by Fosun Pharma. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose or Maximum Administered Dose at 12 months and 2 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
FXS887
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07345637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07345637.